Literature DB >> 2676560

Multiple subsets of HIV-specific cytotoxic T lymphocytes in humans and in mice.

N Chenciner1, F Michel, G Dadaglio, P Langlade-Demoyen, A Hoffenbach, A Leroux, F Garcia-Pons, G Rautmann, B Guy, J M Guillon.   

Abstract

The human immunodeficiency virus type 1 (HIV-1) induces a strong cytotoxic T lymphocyte (CTL) response in humans following infection. HIV-specific CTL can be detected directly in the blood and lungs of infected patients, and can be expanded in vitro by stimulation with autologous HIV-infected lymphoblasts. Furthermore, CTL specific for HIV envelope glycoprotein gp160 have been obtained in mice by immunization with recombinant vaccinia virus (VV) that carry the HIV env gene. In this study, we show that mice also produce strong CTL responses to gag and nef proteins following immunization with VV recombinants, thus providing a convenient model system to study T lymphocyte immunity to defined HIV antigens. To determine the specificity of circulating HIV-immune CTL in humans, a panel of doubly transfected mouse P815 tumor cells was produced which express the human HLA-A2 or HLA-A3 transplantation antigen gene and one HIV-1 gene (env, gag or nef). Using these cells as targets to CTL, we show that HIV-infected humans carry co-existing CTL sub-populations of different specificities. Each subpopulation appears to vary in intensity among different individuals. Surprisingly, CTL specific for regulatory, non-structural nef protein appear to be a major constituent of the human immune response to HIV.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2676560     DOI: 10.1002/eji.1830190904

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  9 in total

1.  Hybrid human immunodeficiency virus Gag particles as an antigen carrier system: induction of cytotoxic T-cell and humoral responses by a Gag:V3 fusion.

Authors:  J C Griffiths; S J Harris; G T Layton; E L Berrie; T J French; N R Burns; S E Adams; A J Kingsman
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

2.  HIV in the lung: guilty or not guilty?

Authors:  C M Mayaud; J Cadranel
Journal:  Thorax       Date:  1993-12       Impact factor: 9.139

3.  HIV-1 Nef protein inhibits the in vitro induction of a specific antibody response to Candida albicans by an early up-regulation of IL-15 production.

Authors:  L Giordani; E Giacomini; M G Quaranta; M Viora
Journal:  Clin Exp Immunol       Date:  2000-12       Impact factor: 4.330

4.  Three epitopic peptides of the simian immunodeficiency virus Nef protein recognized by macaque cytolytic T lymphocytes.

Authors:  I Bourgault; A Venet; J P Levy
Journal:  J Virol       Date:  1992-02       Impact factor: 5.103

5.  Induction of feline immunodeficiency virus-specific cytolytic T-cell responses from experimentally infected cats.

Authors:  W Song; E W Collisson; P M Billingsley; W C Brown
Journal:  J Virol       Date:  1992-09       Impact factor: 5.103

6.  Enhancement of HIV-specific cytotoxic T lymphocyte responses by zidovudine (AZT) treatment.

Authors:  G Dadaglio; F Michel; P Langlade-Demoyen; P Sansonetti; D Chevrier; F Vuillier; F Plata; A Hoffenbach
Journal:  Clin Exp Immunol       Date:  1992-01       Impact factor: 4.330

7.  Fine mapping of HIV-1 Nef-epitopes by monoclonal antibodies.

Authors:  H Siakkou; S Jahn; N Kienzle; R Ulrich; C Grötzinger; T Schneider; B Kohleisen; G Pauli; R Spohn; G Jung
Journal:  Arch Virol       Date:  1993       Impact factor: 2.574

8.  Human immunodeficiency virus (HIV) nef-specific cytotoxic T lymphocytes in noninfected heterosexual contact of HIV-infected patients.

Authors:  P Langlade-Demoyen; N Ngo-Giang-Huong; F Ferchal; E Oksenhendler
Journal:  J Clin Invest       Date:  1994-03       Impact factor: 14.808

9.  Multispecific and heterogeneous recognition of the gag protein by cytotoxic T lymphocytes (CTL) from HIV-infected patients: factors other than the MHC control the epitopic specificities.

Authors:  F Buseyne; G Janvier; B Fleury; D Schmidt; Y Rivière
Journal:  Clin Exp Immunol       Date:  1994-09       Impact factor: 4.330

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.